• Aluminium pouches with a Microwell Plate coated with antibody to mouse TNF-α (8X12)
• 2 vials mouse TNF-α Standard lyophilized, 2000 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-mouse TNF-α antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 4 pieces Adhesive Films
• package insert

The prototype ligand of theTNFsuperfamily, TNF-α/TNFSF1A, is a pleiotropic cytokine that plays a central role in inflammation and apoptosis (1-4).TNF-α is produced by activated macrophages and other cell types including T and B cells, NK cells, LAK cells, astrocytes, endothelial cells, smooth muscle cells and some tumor cells (5-8).

Mouse TNF-α cDNA encodes a 235 amino acid (aa) residue type II membrane protein (9). The 156 aa residue soluble TNF-α is released from the C-terminus of the membrane-anchored TNF-α by proteolytic cleavage by a matrix metalloprotease (10).

The membrane-anchored form of TNF-α has been shown to have lytic activity and may also have an important role in intercellular communication (11). The biologically active TNF-α has been shown to exist as a trimer (12, 13).TNF-α is reported to promote inflammatory cell infiltration by upregulating leukocyte adhesion molecules on endothelial cells, serve as a chemotactic agent for monocytes, and activate phagocyte killing mechanisms (14). Deficiencies in either TNF-α or its receptors can increase susceptibility to infection by intracellular pathogens (15-16). TNF- may also play a role in lymphoid tissue development. Knockout mice lack splenic B cell follicles and the ability to form germinal centers (17, 18). Other potential physiological roles for TNF-α and its receptors include regulating the differentiation of hematopoietic stem and progenitor cells (19-21).

Kwon, B. et al. (1999) Curr. Opin. Immunol. 11:340.

Idriss, H.T. and J.H. Naismith (2000) Microsc. Res. Tech. 50:184.

Sedgwick, J.D. et al. (2000) Immunol. Today 21:110.

MacEwan, D.J. (2002) Brit. J. Pharmacol. 135:855.

Vilcek J. and T.H. Lee (1991) J. Biol. Chem. 266:7313.

Ruddle, N.H. (1992) Curr. Opinion Immunol. 4:327.

Tumor Necrosis Factor: Structure, Function and Mechanism of Action, Aggarwal, B.B. and J. Vilcek eds. (1991) Marcel Dekker, Inc., New York.

Beutler, B. and A. Cerami (1989) Annu. Rev. Immunol. 7:625.

Pennica, D. et al. (1985) Proc. Natl. Acad. Sci. USA 82:6060.

Gearing, A.J.H. et al. (1994) Nature 370:555.

Perez, C. et al. (1990) Cell 63:251.

Jones, E.Y. et al. (1989) Nature 338:225.

Eck, M.J. and S.R. Sprang (1989) J. Biol. Chem. 264:17595.

Wang, C.Y. et al. (1998) Science 281:1680.

Peschon, J.J. et al. (1998) J. Immunol. 160:943.

Wellmer, A. et al. (2001) Infect. Immun. 69:6881.

Trevejo, J.M. et al. (2001) Proc. Natl. Acad. Sci. USA 98:12162.

Kasahara, S. et al. (2003) J. Virol. 77:2469.

Pasparakis, M. et al. (1996) J. Exp. Med. 184:1397.

Taniguchi, T. et al. (1997) Lab. Invest. 77:647.

Jacobsen, F.W. et al. (1994) Proc. Natl. Acad. Sci. USA 91:10695.